MDedge Cardiocast

Alirocumab reduces MIs

Listen

Description

This week in clinical cardiology:

  1. Alirocumab reduces both type 1 and 2 MIs.
  2. Despite failed primary endpoint, MI alert device has predictive value.
  3. Look for alcohol septal ablation in the next HOCM guideline.
  4. FDA: Forty ARBs free of nitrosamines.

You can contact the Cardiocast with ideas, suggestions, stories, or questions for Dr. Dwyer by emailing us at podcasts@mdedge.com and you can follow MDedge Cardiology on Twitter at @MDedgeCardio.